Feasibility of an implantable bioreactor for renal cell therapy using silicon nanopore membranes

Eun Jung Kim, Caressa Chen, Rebecca Gologorsky, Ana Santandreu, Alonso Torres, Nathan Wright, Mark S. Goodin, Jarrett Moyer, Benjamin W. Chui, Charles Blaha, Paul Brakeman, Shant Vartanian, Qizhi Tang, H. David Humes, William H. Fissell and Shuvo Roy ()
Additional contact information
Eun Jung Kim: University of California
Caressa Chen: University of California
Rebecca Gologorsky: University of California
Ana Santandreu: University of California
Alonso Torres: University of California
Nathan Wright: University of California
Mark S. Goodin: SimuTech Group
Jarrett Moyer: University of California
Benjamin W. Chui: University of California
Charles Blaha: University of California
Paul Brakeman: University of California
Shant Vartanian: University of California
Qizhi Tang: University of California
H. David Humes: University of Michigan
William H. Fissell: Silicon Kidney LLC
Shuvo Roy: University of California

Nature Communications, 2023, vol. 14, issue 1, 1-11

Abstract: Abstract The definitive treatment for end-stage renal disease is kidney transplantation, which remains limited by organ availability and post-transplant complications. Alternatively, an implantable bioartificial kidney could address both problems while enhancing the quality and length of patient life. An implantable bioartificial kidney requires a bioreactor containing renal cells to replicate key native cell functions, such as water and solute reabsorption, and metabolic and endocrinologic functions. Here, we report a proof-of-concept implantable bioreactor containing silicon nanopore membranes to offer a level of immunoprotection to human renal epithelial cells. After implantation into pigs without systemic anticoagulation or immunosuppression therapy for 7 days, we show that cells maintain >90% viability and functionality, with normal or elevated transporter gene expression and vitamin D activation. Despite implantation into a xenograft model, we find that cells exhibit minimal damage, and recipient cytokine levels are not suggestive of hyperacute rejection. These initial data confirm the potential feasibility of an implantable bioreactor for renal cell therapy utilizing silicon nanopore membranes.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-39888-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-39888-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-39888-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().